<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599493</url>
  </required_header>
  <id_info>
    <org_study_id>35RC14_9741_EVRIOS</org_study_id>
    <secondary_id>2015-001519-11</secondary_id>
    <secondary_id>150790A-41</secondary_id>
    <secondary_id>15/18-980</secondary_id>
    <nct_id>NCT02599493</nct_id>
  </id_info>
  <brief_title>EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin</brief_title>
  <acronym>EVRIOS</acronym>
  <official_title>EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin in the Treatment of Staphylococcal Bone and Joint Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rifampicin is an antibiotic usually required to treat susceptible Staphylococcus spp.
      osteo-articular infections, most frequently in association with a fluoroquinolone when the
      strain is susceptible to both agents. It is the reference treatment for orthopedic infections
      with implanted material.

      For tuberculosis treatment the dosage of 10 mg/kg/j is usually prescribed, while in the
      treatment of Staphylococcus spp. infections the highest dosage of 20 mg/kg/j is proposed by
      French experts' recommendations from 2009.

      However, there is little evidence in the literature, which could set out arguments to choose
      the best dosage of rifampicin, which may vary from 5 to 20 mg/kg.

      The issue with rifampicin is side effects, in particular with long-term treatment. Many side
      effects may occur in 10 to 20% of patients and sometimes leads to dosage reduction or
      treatment interruption.

      In the literature, there is little evidence that higher rifampicin dosage is associated with
      higher frequency of adverse effects. Depending on the nature of the toxicity, one could say
      that hypersensitivity could be independent from dosage, when digestive disorders may be
      related. Plasmatic concentrations studies have not given strong arguments to link higher
      rifampicin dosages with side effects occurrence rates. After oral absorption, plasmatic peak
      occurs after two to five hours and varies among individuals but also in the same patient
      overtime. This particular pharmacokinetic profile could explain discrepancy in adverse events
      (AEs) frequencies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective :

      To demonstrate that a daily weight-based low dose of rifampicin is non-inferior to a high
      dose in the treatment of susceptible Staphylococcus spp. osteo-articular infections.

      Secondary objectives :

      To compare, in the two treatment groups (weight-based low dose rifampicin versus weight-based
      high dose):

        -  Possible failure rates (when no bacteriological samples are available or when clinical
           manifestations are not straightforward),

        -  AEs distribution:

             -  Those self-patient reported,

             -  Those medical or biological reported,

        -  - Rifampicin dose modifications:

             -  Dosage decrease,

             -  Treatment interruption (temporary or definitive),

        -  Failure risk factors analysis,

        -  Health costs related to the osteo-articular infection care: number and length of
           hospitalizations, number of follow-up visits, nature and number of all biological
           samples prescribed in both groups.

        -  Comparison of the planned rifampicin exposure in each randomization group

        -  Differences in rifampicin duration (planned versus effective duration) according to
           allocated group,

        -  Rifampicin pharmacokinetics sub-study in a small sample of 60 patients,

        -  Rifampicin resistance bacteriological study in patients with proven failure.

      Methodology :

      Non-inferiority prospective, multicentre, randomized, open-label, controlled phase IV trial
      evaluating two different rifampicin dosages (high versus low dose) in the treatment of
      staphylococcal bone and joint infections.

      Treatment :

      Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage
      (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with
      another antibiotic chosen by investigator according to the antibiogram results. Association
      with fluoroquinolones is the first choice combination, if it is possible. The global
      antibiotic treatment duration depends on the investigator's choice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proven failure</measure>
    <time_frame>12 months</time_frame>
    <description>The rate of proven failure between the two groups, 12 months after the end of antibiotics.
The proven failure is defined as a documented bacteriological failure, with the same Staphylococcus spp. strain isolated before the onset of antibiotics and at diagnosis of failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Possible failure</measure>
    <time_frame>12 months</time_frame>
    <description>Possible failure rates: defined as the lack of documented bacteriology and presence of septic clinical manifestations according to French experts recommendations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biological and clinical AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose modification</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rifampicin dose modification: each rifampicin dosages change or interruption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure risk factors</measure>
    <time_frame>12 months</time_frame>
    <description>Failure risk factors: collected for each patient and include those already known in the literature: bacterial strains type, anatomic site of infection, presence of prosthetic material, duration of infectious signs, waiting period between first infectious signs and medical care, type of surgical intervention (with or without prosthetic material removal), type, duration and administration road of antibiotics treatment, patient's age, concomitant pathologies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global health costs</measure>
    <time_frame>12 weeks</time_frame>
    <description>Global health costs: rhythm of visits defined by investigator site until the end of antibiotic treatment, all additional visit and/or exams or concomitant treatment prescriptions will be collected at each schedule visit, analysed and compared in two groups of rifampicin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Real antibiotics treatment duration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Real antibiotics treatment duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>12 hours</time_frame>
    <description>Rifampicin Pharmacokinetic: it will be studied in a sub-sample of 60 patients (30 in each group) at the onset of rifampicin-based regimen and will estimate rifampicin plasmatic concentration, self-induction mechanism and possible links with ARs or adverse occurrences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Staphylococcus spp. resistance</measure>
    <time_frame>12 months</time_frame>
    <description>Analysis of Staphylococcus spp. resistance: in case of proven failure, will compare strains in the same patient and resistant strains incidence into the two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Osteoarticular Infection</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomly assigned to high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.</description>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
    <other_name>RIMACTAN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (over 18 years old) who gave their signed inform consent,

          -  Who present an osteo-articular infection with susceptible Staphylococcus spp.,

          -  To whom a rifampicin based regimen is prescribed, in association with another
             antibiotic, for at least 14 days,

          -  Patients covered by Health Insurance.

        Exclusion Criteria:

          -  Patients weighing less than 45 kg or more than 150 kg,

          -  Patients with active TB (whatever its localization),

          -  Presence or anticipated need during the study period, of drugs contraindicated with
             rifampicin: anticalcineurins, protease inhibitors and nevirapine,

          -  Patients with a known and documented rifampicin allergy.

          -  Pregnant or breastfeeding woman,

          -  Adults legally protected (under judicial protection, guardianship or supervision),
             persons deprived of their liberty,

          -  Patients participating in another interventional clinical trial (biomedical trial or
             standard care clinical trial).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cédric ARVIEUX, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>cedric arvieux, md</last_name>
    <email>cedric.arvieux@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jean-marc chapplain, md</last_name>
    <email>jean-marc.chapplain@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Angers university hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Abgueguen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Abgueguen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux university hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Dupon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michel Dupon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brest university hospital</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Séverine Ansart, MD</last_name>
    </contact>
    <investigator>
      <last_name>Séverine Ansart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen university hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud Verdon</last_name>
    </contact>
    <investigator>
      <last_name>Renaud Verdon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Roche sur Yon hospital</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Guimard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Guimard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lorient hospital</name>
      <address>
        <city>Lorient</city>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien Lorleac'h, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélien Lorleac'h, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Le Moing, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Le Moing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes university hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Asseray, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nathalie Asseray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pau hospital</name>
      <address>
        <city>Pau</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Gaborieau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Valérie Gaborieau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poitiers university hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>France Roblot</last_name>
    </contact>
    <investigator>
      <last_name>France Roblot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes university hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric ARVIEUX, MD</last_name>
      <email>cedric.arvieux@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Cédric ARVIEUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Brieuc hospital</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude Beuscart, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rodolphe Buzelé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Malo hospital</name>
      <address>
        <city>Saint-Malo</city>
        <zip>35400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien Fily, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabien Fily, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse university hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>35059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Delobel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Delobel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours university hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Bernard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Louis Bernard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Rosset, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe Rosset, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nancy university hospital</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sibylle Bevilacqua, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sibylle Bevilacqua, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vannes hospital</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Poinsignon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yves Poinsignon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyon university hospital</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Issartel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand Issartel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

